These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8933293)

  • 21. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with alloxan-induced diabetes mellitus.
    Kim SH; Kim WB; Lee MG
    Biopharm Drug Dispos; 1998 Jul; 19(5):303-8. PubMed ID: 9673782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
    Darvari R; Boroujerdi M
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant disease.
    Morgan DJ; Hill JS; Clarke K; Stylli SS; Park SJ; Cebon J; Basser RL; Kaye AH; Geldard H; Maher DW; Green MD
    Cancer Chemother Pharmacol; 1997; 40(3):202-8. PubMed ID: 9219502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of mequindox and its metabolites in rats after intravenous and oral administration.
    Li G; Yang F; He L; Ding H; Sun N; Liu Y; Liu Y; Shan Q; Li Y; Zeng Z
    Res Vet Sci; 2012 Dec; 93(3):1380-6. PubMed ID: 22459092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE; Mayer LD
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats.
    Lee HJ; Lee MG
    Res Commun Mol Pathol Pharmacol; 1999; 105(1-2):87-96. PubMed ID: 10850372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of protein-calorie malnutrition on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats.
    Bae SK; Lee SJ; Kwon JW; Kim WB; Lee MG
    J Pharm Pharmacol; 2004 May; 56(5):635-42. PubMed ID: 15142341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of ethylene glycol. III. Plasma disposition and metabolic fate after single increasing intravenous, peroral, or percutaneous doses in the male Sprague-Dawley rat.
    Frantz SW; Beskitt JL; Tallant MJ; Zourelias LA; Ballantyne B
    Xenobiotica; 1996 May; 26(5):515-39. PubMed ID: 8736063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
    J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of intravenously administered stealth liposomal doxorubicin modulated with verapamil in rats.
    Wang JC; Liu XY; Lu WL; Chang A; Zhang Q; Goh BC; Lee HS
    Eur J Pharm Biopharm; 2006 Jan; 62(1):44-51. PubMed ID: 16126379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of water deprivation on the pharmacokinetics and pharmacodynamics of bumetanide in rats.
    Huang JY; Kim ON; Lee SH; Lee MG
    Biopharm Drug Dispos; 1993 Aug; 14(6):463-74. PubMed ID: 8218964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats.
    Han KS; Kim YG; Yoo JK; Lee JW; Lee MG
    Biopharm Drug Dispos; 1998 Nov; 19(8):493-500. PubMed ID: 9840211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure.
    Kim SH; Shim HJ; Kim WB; Lee MG
    Antimicrob Agents Chemother; 1998 May; 42(5):1217-21. PubMed ID: 9593153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects.
    Kim EJ; Lee MG
    Biopharm Drug Dispos; 2001 May; 22(4):147-56. PubMed ID: 11745917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate-salt-induced hypertensive rats.
    Kim SH; Kim WB; Lee MG
    Drug Metab Dispos; 1999 Jun; 27(6):710-6. PubMed ID: 10348801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition.
    Kim SH; Choi YM; Lee MG
    J Pharmacokinet Biopharm; 1993 Feb; 21(1):1-17. PubMed ID: 8410679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats.
    Lee SJ; Bae SK; Kwon JW; You M; Lee DC; Lee MG
    J Pharm Pharmacol; 2005 Nov; 57(11):1397-405. PubMed ID: 16259771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
    Mita MM; Natale RB; Wolin EM; Laabs B; Dinh H; Wieland S; Levitt DJ; Mita AC
    Invest New Drugs; 2015 Apr; 33(2):341-8. PubMed ID: 25388939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 6th communication: interspecies comparison of pharmacokinetics and excretion of imidapril metabolites in rats, dogs, and monkeys.
    Yamada Y; Endo M; Kohno M; Otsuka M; Takaiti O
    Arzneimittelforschung; 1992 Apr; 42(4):499-506. PubMed ID: 1642673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.